A compound of general formula (I): ** Formula ** its tautomers, geometric isomers E and Z, optically active forms, such as enantiomers, diastereomers and their racemate forms or a mixture of stereoisomeric forms or their pharmaceutically acceptable salts of the same or complex thereof； wherein Z1 is independently selected from the group consisting of: -CnH (2n) -, which is branched or unbranched in which n is an integer from 1 to 5； -CnH (2n-2) - in E or Z geometric conformation that is branched or unbranched in which n is an integer from 2 to 5； -CnH (2n-4) - which is branched or unbranched in which n is an integer from 2 to 5； -CR'H-, -C2H3R'-, E or Z -C2HR'-, -C3H5R'-, E or Z -C3H3R '-, - OCH2-, -CH2O-, NR "CH2 -, - CH2NR" -； wherein R 'is independently selected from the group consisting of: -H, halogen, -NH2, -OH, -CN, CF3, -CHF2, -CH2F, -SH, - SCN, -CH3, -C2H5； wherein R "is independently selected from the group consisting of: -H, -CH3, -C2H5； in which R1 and R2 are independently selected from the group consisting of aromatic ring or heteroaromatic ring, as a modulator of a CFTR protein mutant for use in the treatment of cystic fibrosis.Un compuesto de fórmula general (I):**Fórmula** sus tautómeros, los isómeros geométricos E y Z, las formas ópticamente activas, tales como enantiómeros, diastereómeros y sus formas racemato o una mezcla de formas estereoisoméricas o sus sales farmacéuticamente aceptables de los mismos o complejos de los mismos； en la que Z1 se selecciona independientemente del grupo que consiste en: -CnH(2n)-, que está ramificado o no ramificado en el que n es un número entero de 1 a 5； -CnH(2n-2)- en E o Z conformación geométrica que está ramificada o no ramificada en la que n es un número entero de 2 a 5； -CnH(2n- 4)- que está ramificada o no ramificada en la que n es un número entero de 2 a 5； -CR'H-, -C2H3R'-, E o Z -C2HR'- , -C3H5R'-, E or Z -C3H3R'-,-OCH2-, -CH2O-, NR"CH2-,-CH2NR"-； en los que R' se selecciona independientemente del grupo
